Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if Dasatinib is effective and safe to give to
people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the
drug on LYN kinase activity in blood and bone marrow. Recent research shows that a key enzyme
in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory
studies show that inhibition of LYN kinase in CLL cells results in the death to CLL cells.
Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on
CLL cells.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Bristol-Myers Squibb Dana-Farber Cancer Institute